Author(s):
Rana Khan, Aizaz Ahmed Khan, Nuha Rasheed, Abdul Saleem Mohammad
Email(s):
mohdsaleempharma@gmail.com
DOI:
10.5958/2231-5713.2017.00012.5 
Address:
Rana Khan1*, Aizaz Ahmed Khan2, Nuha Rasheed3, Abdul Saleem Mohammad4
1Department of Pharma. D, Nizam Institute of Pharmacy, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Yadadri (Dist)-508284, Telangana, India.
2Department of Engineering and Technology, Nizam Institute of Engineering and Technology, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Yadadri (Dist)-508284, Telangana, India.
3Department of Pharmaceutics, Nizam Institute of Pharmacy, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Yadadri (Dist)-508284, Telangana, India.
4Department of Pharmaceutical Analysis and Quality Assurance, Nizam Institute of Pharmacy, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Yadadri (Dist)-508284, Telangana, India.
*Corresponding Author
Published In:
Volume - 7,
Issue - 2,
Year - 2017
ABSTRACT:
The development of radiotraces with defined affinities for specific receptor systems is a potentially useful approach to the design of radio pharmaceuticals for nuclear medicine. Radio labeled ligands, such as hormones and neurotransmitters, are being synthesized and evaluated as diagnostic tools for diseases which can be characterized either by changes in receptor concentration or by novel receptor expression. Since the utility of a radio pharmaceutical is dependent upon the achievement of adequate ratios of target to non-target accumulation of radio activity, design of radio traces via the receptor approach attempts to exploit those systems in which receptor is present in significantly higher concentration at potential target sites such as tumors. Receptor-mediated radio tracers are also currently being used in animal models to investigate the normal tissue distribution of drug and hormone receptors and the in-vivo pharmacokinetics of receptor binding. The successful development of receptor-avid radiopharmaceuticals will depend upon the ability to synthesize ligands of high specific radio activity which retain the high affinity and binding specifically for the receptor after radio labeling.
Cite this article:
Rana Khan, Aizaz Ahmed Khan, Nuha Rasheed, Abdul Saleem Mohammad. Current Trends in Radio- Pharmaceuticals. Asian J. Pharm. Tech. 2017; 7(2): 77-79. doi: 10.5958/2231-5713.2017.00012.5
Cite(Electronic):
Rana Khan, Aizaz Ahmed Khan, Nuha Rasheed, Abdul Saleem Mohammad. Current Trends in Radio- Pharmaceuticals. Asian J. Pharm. Tech. 2017; 7(2): 77-79. doi: 10.5958/2231-5713.2017.00012.5 Available on: https://ajptonline.com/AbstractView.aspx?PID=2017-7-2-4